Anti-Mouse CD106 (VCAM-1) (Clone M/K-2.7) – Purified in vivo GOLD™ Functional Grade
Anti-Mouse CD106 (VCAM-1) (Clone M/K-2.7) – Purified in vivo GOLD™ Functional Grade
Product No.: C2491
Clone M/K-2.7 Target CD106 (VCAM-1) Formats AvailableView All Product Type Hybridoma Monoclonal Antibody Alternate Names VCAM-1, INCAM-110 Isotype Rat IgG1 κ Applications IF , in vivo , N |
Antibody DetailsProduct DetailsReactive Species Mouse Host Species Rat Recommended Dilution Buffer Immunogen Stromal cells derived from mouse bone marrow Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Regulatory Status Research Use Only Country of Origin USA Shipping 2 – 8° C Wet Ice Additional Applications Reported In Literature ? IF, in vivo, N Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity The M/K-2.7 activity is specifically directed against mouse CD106 also known as VCAM-1 and
INCAM-110. Background CD106 is a single-chain type I glycoprotein with a molecular weight of 110 kDa. It is upregulated in
response to inflammatory stimuli and cytokines, and it plays an important role in leukocyte adhesion,
transmigration, and T-cell proliferation by binding to integrins CD49d/CD29 (VLA-4) and α4β71. It has
implications in several pathologies, including heart diseases, inflammation, and cancer metastasis2. The
regulation and function of CD106 in immune responses highlight its potential as a therapeutic target in
treating these conditions. The M/K-2.7 clone was developed using stromal cells derived from mouse bone marrow as the immunogen. It has been widely used in various research contexts, particularly in studies involving in vivo VCAM-1 neutralization, immunofluorescence techniques, and more. This clone demonstrates its versatility across a range of experimental setups and is a valuable tool for investigating vascular cell adhesion mechanisms and the inflammatory process. It is particularly useful for research focused on inflammatory processes, immune cell migration, and the study of vascular biology3-6. Antigen Distribution CD106 is predominantly expressed on activated vascular endothelial cells, as well
as on various other cells including follicular and interfollicular dendritic cells, some macrophages, and
bone marrow stromal cells. Its expression can also be found in non-vascular cells within joints, kidneys,
muscles, the heart, the placenta, and the brain. Ligand/Receptor VLA-4 (α4/β1 integrin) and LPAM-1 (α4/β7 integrin) NCBI Gene Bank ID UniProt.org Research Area Cell Adhesion . Cell Biology . Immunology . Neuroinflammation . Neuroscience . CD Molecules . Stem Cells Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone M/K-2.7 is a rat monoclonal antibody that specifically targets mouse CD106 (VCAM-1), and it is commonly used in vivo for VCAM-1 neutralization studies in mice. Key in vivo applications in mice include:
Additional relevant details:
In summary, clone M/K-2.7 is primarily used for VCAM-1 neutralization and to dissect the role of VCAM-1 in immune cell trafficking, inflammation, and cardiovascular or tissue injury models in mice. The M/K-2.7 antibody targets mouse CD106 (VCAM-1), and in published research, it is frequently used with other antibodies and proteins related to immune cell markers, endothelial cell markers, and adhesion molecules, depending on specific study aims. Commonly co-used antibodies/proteins include:
Experimental applications:
Summary Table: Common co-used targets/proteins
The panel composition may vary based on whether the study focuses on immunology, vascular biology, or in vivo cell trafficking. For additional details on experimental combinations, flow panels, or molecular interactions, review primary literature or specific protocols cited in the manufacturer datasheets. The clone M/K-2.7 is a widely cited rat monoclonal antibody targeting mouse CD106 (VCAM-1), primarily used for research on vascular biology, inflammation, immune cell trafficking, and transplant immunology. Key findings from scientific literature using clone M/K-2.7 include:
In summary: Clone M/K-2.7 has been foundational in demonstrating VCAM-1’s roles in endothelial activation, immune cell migration, graft rejection, and in providing a valuable tool for dissecting the molecular mechanisms of immune responses in mouse disease models. Dosing regimens of clone M/K-2.7 (anti-mouse CD106/VCAM-1) vary by disease model, study aim, and can differ in frequency, dose, and administration route in mouse studies. The most frequently reported regimen is:
Variations Across Mouse Models
Considerations
Mechanistic NoteClone M/K-2.7 is a rat IgG1 monoclonal antibody that binds and neutralizes mouse VCAM-1, potentially affecting immune cell adhesion and trafficking, so its use can influence results in various disease and immunological contexts. Summary Table: Reported Regimens
Reported regimens for clone M/K-2.7 remain relatively consistent in dosing amount and frequency, with small adjustments for disease model or experimental goals. If highly specific regimens for other disease models or genetically modified mice are required, consult recent primary literature matching your research focus. References & Citations1. Tolstrup A, Hokland P, Nielsen B, Justesen J, Hokland M. J Interferon Res. 1993;13(6):433-441. 2. Salajegheh A, Salajegheh A. Springer International Publishing; 2016:375-379. 3. Hession C, Moy P, Tizard R, et al. Biochem Biophys Res Commun. 1992;183(1):163-169. 4. Osborn L, Hession C, Tizard R, et al. Cell. 1989;59(6):1203-1211. 5. Miyake K, Medina K, Ishihara K, Kimoto M, Auerbach R, Kincade PW. The Journal of cell biology. 1991;114(3):557-565. 6. Kumar AG, Dai XY, Kozak CA, Mims MP, Gotto AM, Ballantyne CM. The Journal of Immunology. 1994;153(9):4088-4098. 7. Yousef H, Czupalla CJ, Lee D, et al. Nat Med. 2019;25(6):988-1000. 8. de Juan A, Ince LM, Pick R, et al. Circulation. 2019;140(13):1100-1114. 9. He W, Holtkamp S, Hergenhan SM, et al. Immunity. 2018;49(6):1175-1190.e7. 10. Kapitsinou PP, Sano H, Michael M, et al. J Clin Invest. 2014;124(6):2396-2409. 11. Chow A, Huggins M, Ahmed J, et al. Nat Med. 2013;19(4):429-436. 12. Brinkman CC, Rouhani SJ, Srinivasan N, Engelhard VH. J Immunol. 2013;191(5):2412-2425. 13. Thomas SY, Scanlon ST, Griewank KG, et al. J Exp Med. 2011;208(6):1179-1188. |
Formats Available
